UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

21069

7590

03/22/2010

AMGEN INC. MAIL STOP 28-2-C ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320-1799 EXAMINER

SZPERKA, MICHAEL EDWARD

PAPER NUMBER

ART UNIT

DATE MAILED: 03/22/2010

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/211,297      | 12/14/1998  | WILLIAM J. BOYLE     | A-451M              | 7253             |

TITLE OF INVENTION: ANTIBODIES TO OSTEOPROTEGERIN BINDING PROTEINS

| APPLN. TYPE    | SMALL ENTITY | ISSUE FEE DUE | PUBLICATION FEE DUE | PREV. PAID ISSUE FEE | TOTAL FEE(S) DUE | DATE DUE   |
|----------------|--------------|---------------|---------------------|----------------------|------------------|------------|
| nonprovisional | NO           | \$1510        | \$300               | \$0                  | \$1810           | 06/22/2010 |

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

## PART B - FEE(S) TRANSMITTAL

## Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where m

| CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)  21069 7590 03/22/2010  AMGEN INC.  MAIL STOP 28-2-C ONE AMGEN CENTER DRIVE   |   |                                       |  | Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.  Certificate of Mailing or Transmission  I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. |                         |  |  |
|--|---|---------------------------------------|--|--|-------------------------|--|--|
|  |   |                                       |  |  |                         |  |  |
|  |   |                                       |  |  |                         | (Signature)  |  |
|  |   |                                       |  |  |                         | (Date)   |  |
| APPLICATION NO.  | FILING DATE   |                                       | FIRST NAMED INVENTO  | R  | ATTORNEY DOCKET N       | O. CONFIRMATION NO.  |  |
| 09/211,297   | 12/14/1998  | •                                     | WILLIAM J. BOYLE   |  | A-451M                  | 7253   |  |
| TITLE OF INVENTION   | N: ANTIBODIES TO OS   | TEOPROTEGERIN BIN                     | DING PROTEINS  | _  |                         |  |  |
| APPLN. TYPE  | SMALL ENTITY  | ISSUE FEE DUE                         | PUBLICATION FEE DUI  | E PREV. PAID ISSU  | E FEE TOTAL FEE(S)      | DUE DATE DUE   |  |
| nonprovisional   | NO  | \$1510                                | \$300  | \$0  | \$1810                  | 06/22/2010   |  |
| EXAM   | IINER   | ART UNIT                              | CLASS-SUBCLASS   | ╛  |                         |  |  |
| SZPERKA, MIC   | HAEL EDWARD   | 1644                                  | 530-387900   |  |                         |  |  |
| CFR 1.363).  ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. |   |                                       | or agents OR, alterna<br>(2) the name of a sin<br>registered attorney o<br>2 registered patent at  | (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,  (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.  |                         |  |  |
| PLEASE NOTE: Un<br>recordation as set for<br>(A) NAME OF ASSI  | less an assignee is ident<br>th in 37 CFR 3.11. Comj<br>GNEE  | oletion of this form is NO            | data will appear on the<br>T a substitute for filing a<br>(B) RESIDENCE: (CIT  | patent. If an assign<br>n assignment.<br>'Y and STATE OR (   | COUNTRY)                | te group entity  Government  |  |
|  |   |                                       | •  |  | -                       |  |  |
| 4a. The following fee(s) are submitted:  ☐ Issue Fee ☐ Publication Fee (No small entity discount permitted) ☐ Advance Order - # of Copies  |   |                                       | 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)  ☐ A check is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached. ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number (enclose an extra copy of this form). |  |                         |  |  |
| 5. Change in Entity Sta  | atus (from status indicate  | · · · · · · · · · · · · · · · · · · · |  |  | LL ENTITY status. See 3 |  |  |
| NOTE: The Issue Fee an   | nd Publication Fee (if req  |                                       | d from anyone other than   |  |                         | or the assignee or other party in  |  |
|  |   |                                       |  | Data   |                         |  |  |
| Authorized Signature   |   |                                       |  |  |                         |  |  |
| This collection of information is required by 37 CFR 1.311. The information  |   |                                       |  | _  |                         |  |  |
| an application Confider  | ntiality is governed by 35 dapplication form to the ions for reducing this bu Virginia 22313-1450. DO | ILS C 122 and 37 CER                  | 1.14 This collection is a  | stimated to take 12  | minutes to complete inc | e (and by the USP1O to process)<br>luding gathering, preparing, and<br>of time you require to complete<br>Department of Commerce, P.O.<br>oner for Patents, P.O. Box 1450, |  |

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

OMB 0651-0033

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO   | O.         | FILING DATE | FIRST NAMED INVENTOR           | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|------------|-------------|--------------------------------|---------------------|------------------|
| 09/211,297   |            | 12/14/1998  | WILLIAM J. BOYLE               | A-451M              | 7253             |
| 21069  | 7590       | 03/22/2010  |                                | EXAM                | IINER            |
| AMGEN IN   | AMGEN INC. |             |                                | SZPERKA, MICI       | HAEL EDWARD      |
| MAIL STOP  |            | ,           |                                | ART UNIT            | PAPER NUMBER     |
| ONE AMGEN CENTER DRIVE<br>THOUSAND OAKS, CA 91320-1799 |            |             | 1644<br>DATE MAILED: 03/22/201 | 0                   |                  |

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

|   | Application No.  | Applicant(s)  |                 |
|---|--|---|-----------------|
|   | 09/211,297   | BOYLE, WILLIAM J.   |                 |
| Notice of Allowability  | Examiner   | Art Unit  |                 |
|   | Michael Szperka  | 1644  |                 |
|   | Michael Szperka  | 1044  |                 |
| The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313                                   | (OR REMAINS) CLOSED<br>or other appropriate comr<br>IGHTS. This application is | in this application. If not included nunication will be mailed in due course. | THIS initiative |
| 1. This communication is responsive to 16 February 2010.  |  |   |                 |
| 2. The allowed claim(s) is/are <u>93-103</u> .  |  |   |                 |
| <ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority units.</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have</li> <li>2. ☐ Certified copies of the priority documents have</li> <li>3. ☐ Copies of the certified copies of the priority do</li> </ul> | e been received.<br>e been received in Applica                                 | ion No  | n the           |
| International Bureau (PCT Rule 17.2(a)).  |  | 3 11  |                 |
| * Certified copies not received:  |  |   |                 |
| Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.   |  | le a reply complying with the requireme                                       | nts             |
| 4. A SUBSTITUTE OATH OR DECLARATION must be subm<br>INFORMAL PATENT APPLICATION (PTO-152) which give  |  |   | OF              |
| 5. CORRECTED DRAWINGS ( as "replacement sheets") must   | st be submitted.   |   |                 |
| (a) I including changes required by the Notice of Draftspers  | son's Patent Drawing Revi  | ew ( PTO-948) attached  |                 |
| 1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date  |  |   |                 |
| <ul><li>(b) ☐ including changes required by the attached Examiner'</li><li>Paper No./Mail Date</li></ul>  | s Amendment / Comment  | or in the Office action of  |                 |
| Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t  |  |   | of              |
| 6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT  |  |   | :               |
|   |  |   |                 |
| Attachment(s)   |  |   |                 |
| 1. Notice of References Cited (PTO-892)   |  | Informal Patent Application   |                 |
| 2. Notice of Draftperson's Patent Drawing Review (PTO-948)  |  | Summary (PTO-413),<br>b./Mail Date  |                 |
| 3. ☑ Information Disclosure Statements (PTO/SB/08),   | 7. ☐ Examiner  | s Amendment/Comment   |                 |
| Paper No./Mail Date <u>7/17/06, 5/14/07, 10/14/08, 2/16/10</u> 4. ☐ Examiner's Comment Regarding Requirement for Deposit  | ⊠ Evaminor   | s Statement of Reasons for Allowance  |                 |
| of Biological Material  |  |   |                 |
|   | 9. ☐ Other   | <u> </u>  |                 |
| /Michael Szperka/<br>Primary Examiner, Art Unit 1644  |  |   |                 |
| Timary Examiner, Art Offic 1044   |  |   |                 |
|   |  |   |                 |

Application/Control Number: 09/211,297 Page 2

Art Unit: 1644

## **DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 16, 2010 has been entered.

Claims 1-92 have been canceled.

Claims 93-103 are pending in the instant application.

Applicant's response and amendments received February 16, 2010 have overcome all prior grounds of objection and rejection.

Specifically, the objection to independent claims 93 and 103 has been withdrawn in view of applicant's claim amendments to insert the word "protein" between "osteoprotegerin binding" and "of SEQ ID NO:".

Additionally, applicant has supplied evidence in the form of declarations and affidavits which provide evidence that the antibodies claimed in the instant application bind to epitopes of osteoprotegerin binding protein which are distinct from epitopes bound by antibodies claimed in both previously issued and presently copending applications. Thus, the double patenting rejections have been withdrawn.

Claims 93-103 are allowable.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is (571)272-2934. The examiner can normally be reached on M-F 8:00-4:30.

Application/Control Number: 09/211,297 Page 3

Art Unit: 1644

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Szperka, Ph.D. Primary Examiner Art Unit 1644

/Michael Szperka/ Primary Examiner, Art Unit 1644